Top Industry Leaders in the Cancer Biologic Therapy Market
Latest Cancer Biological Therapy Companies Update
Bristol Myers Squibb (US) acquires Turning Point Therapeutics (US) for $3.2 billion, gaining access to TP-598, a promising T-cell receptor therapy for solid tumors. (Jan 2024)
Roche (Switzerland) announces plans to purchase biotech company ImmunoGen (US) for $5.8 billion, strengthening its portfolio of antibody-drug conjugates for cancer treatment. (Dec 2023)
Pfizer (US) acquires cell therapy developer Vivant Biosciences (US) for $2.5 billion, aiming to expand its offerings in CAR-T cell therapy. (Nov 2023)
AstraZeneca (UK) receives FDA approval for Imfinzi (durvalumab) for the treatment of non-small cell lung cancer in combination with chemotherapy. (Jan 2024)
Merck & Co. (US) launches Keytruda (pembrolizumab) for the first-line treatment of advanced head and neck cancer. (Dec 2023)
Johnson & Johnson (US) unveils Tecentriq (atezolizumab) for the treatment of triple-negative breast cancer in combination with chemotherapy. (Nov 2023)
List of Cancer Biological Therapy companies in the market
- Amgen Inc.
- Bristol-Myers Squibb
- Celgene Corporation
- ELI Lilly and Company
- Hoffmann-La Roche AG
- EnGeneIC Ltd
- Merck & Co. Inc.
- Novartis, Pfizer Inc.